How much does a Keytruda treatment cycle cost?
Keytruda (pembrolizumab), Merck's PD-1 inhibitor for cancers like melanoma and lung cancer, has a wholesale acquisition cost (WAC) of about $11,389 per 100 mg/4 mL vial or $10,824 per 200 mg/20 mL vial in the US as of 2024.[1] Most patients receive 200 mg every three weeks, so one dose costs around $10,800-$11,000 before discounts.
A typical 12-week cycle (4 doses) runs $43,000-$44,000 at list price. Annual treatment (17 doses) exceeds $180,000.[2]
What do patients actually pay with insurance or assistance?
List prices rarely reflect out-of-pocket costs. Commercial insurance covers 90-95% after copays of $0-$500 per month via copay accumulators or Merck's patient assistance programs.[3] Medicare patients average $1,500-$3,000 monthly after Part B (20% coinsurance on ~$11,000/dose), often reduced by $0 copay cards for eligible commercial plans.[4]
Uninsured patients qualify for Merck's free drug program if income is under 500% of federal poverty level (~$75,000 for a family of four).[1]
Why is Keytruda so expensive and how has pricing changed?
High costs stem from R&D, manufacturing biologics, and market exclusivity. US list price rose 6-8% annually pre-2023 but stabilized after Inflation Reduction Act caps Medicare increases at inflation.[5] Internationally, prices are 40-70% lower (e.g., ~$4,000/dose in Canada, $3,500 in UK).[6]
No generic exists due to biologics exclusivity until 2028, though biosimilars loom post-patent (2030-2035 for key claims).[7]
How does Keytruda pricing compare to competitors?
| Drug | Per-Dose Cost (200 mg equiv.) | Annual Estimate |
|------|-------------------------------|-----------------|
| Keytruda | $10,800 | $184,000 |
| Opdivo (BMS) | $12,500 | $212,000 |
| Tecentriq (Roche) | $11,760 | $200,000 |
| Imfinzi (AstraZeneca) | $14,500 | $246,000[2][8] |
Keytruda undercuts rivals slightly but dominates with 50%+ market share in PD-1s.[9]
When might costs drop and what are the risks?
Biosimilars could enter 2028-2030 after pediatric exclusivity ends December 2027, potentially halving prices like Humira's drop.[7] Patent challenges from Amgen and others are ongoing; Merck defends core composition patents to 2035.[10]
Patients face access risks if insurers shift to cheaper alternatives or prior authorizations tighten amid 340B discounts (50% off list).[11]
Sources
[1]: DrugPatentWatch.com - Keytruda Pricing
[2]: GoodRx - Keytruda Costs
[3]: Merck Access Program
[4]: CMS Medicare Data
[5]: Inflation Reduction Act Summary
[6]: IQVIA Global Pricing Report
[7]: DrugPatentWatch.com - Keytruda Patents
[8]: Evaluate Pharma
[9]: Statista PD-1 Market Share
[10]: USPTO Litigation Tracker
[11]: GAO 340B Report